

**Patent Details**

**Patent Number** 331532    **Current Status** Granted and Sealed

**International Application Number**

**WO Publication Number**

**Patent Type** Patent Convention

**Patent Title** Multilayered metal stent

**Filed** 25-AUG-1998

**Convention**              **Date** 13-NOV-1997    **Country** United States of America    **App No:** 97 969576

**Renewal Date** 25-AUG-2005

**Class**


**Classification**              **Schedule and Edition**

IPC|A61F2/06              IPC4

**Documents**

**Abstract/Abridgement**              Document 2.8 Kb

**Drawing**



**Applicant / Patente:** MEDINOL LTD . Kiryat Atidim, P.O.B. 58165, Tel Aviv, 61581, Israel

**Contact :** HENRY HUGHES . Patent Attorneys, 119-125 Willis Street, Wellington, New Zealand

**Service Address :** As above

Action	Completed	Due	Journal	Published
Renew	13-AUG-2002	25-AUG-2002	1478	30-AUG-2002
Renewal Notice	28-MAY-2002	28-MAY-2002		
Registered	12-MAY-2000		1451	26-MAY-2000
Published Date	28-JAN-2000			
Application Accepted	15-DEC-1999	15-DEC-1999	1447	28-JAN-2000
Filed	25-AUG-1998	25-AUG-1998		

**Related Patents**

No Related Patents found

**Objections / Hearings**

There are no current objections or hearings present

**Renewal Interest**

COMPUTER PATENT ANNUITIES PO Box 778, Jersey, JE1 1BL, Channel Islands

**Applicant / Patentee & Licensee History**

No applicants nor licensees on record or public access is restricted

**Inventors**

Richter, Jacob

---

**Your Selection Criteria**

IPOL Database Search

**Collection:** Public

**Schedule:** IPC

**Patent Number:** 331532

The information contained in the databases accessible through this site has been taken from files held at the Intellectual Property Office of New Zealand. This site is not intended to be a comprehensive or complete source of intellectual property information. The Intellectual Property Office will not be liable for the provision of any incorrect or incomplete information.

To obtain further assistance on the use of this Internet site please contact webmaster@companies.govt.nz or free-phone 0508 266726. Mobile and international callers telephone (03) 962 2602. To obtain information on how to apply for a patent, trade mark or design telephone (04) 560 1600.

Delivered: 29th May 2003 04:37:36



Intellectual Property Office of New Zealand  
IP Summary Report

Page: 1 / 1  
Date: 15 December 1999  
Time: 12:53:57  
(Iprip02 2.00.16)

(51) Classification: A61F2/06 IPC Edition: IPC Status: 70 Accepted Version number: 3  
Client Ref: P15768 IP type: Patent Convention

331532

(22) NZ Filing date: 23 August 1998 Date actions completed:  
(30) Priority Data: (31) 97 969576 (32) 13 November 1997 (33) Application Accepted 15 December 1999  
US

Next renewal date: 13 November 2001

(71) Applicant: MEDINOL LTD, PO Box 58165, Kiryat Atidim, Bidg 3, Tel Aviv 61581, Israel

(72) Inventor: Richter, Jacob  
Contact: HENRY HUGHES, Level 9, Westpac Trust Investment House, 119-125 Willis St, Wellington, NZ

Primary Examiner: MIKE GAMBITSIS  
Journal: 1447

Office title: Stents for deploying in body lumens comprising a tubular body having a radiopaque coating

(54) Applicant title: Multilayered metal stent

(57) Abstract:

Patent 331532

A stent 100 for deploying within a body lumen comprises a tubular member 101 comprising struts 110 which comprise a first material. The tubular member has a proximal end and a distal end and a longitudinal bore therethrough. A first coating 102 – not shown, on tubular member 101 covers tubular member and is uniform in thickness. The first coating contains a second material which is more opaque than the first material.

" End of report "

## MULTILAYERED METAL STENT

### FIELD OF THE INVENTION

The present invention relates to stents for  
5 deploying within body lumens, and more particularly, to  
optimizing the radiopacity of such stents.

### BACKGROUND

Stents are tubular structures that are implanted  
10 inside bodily conduits, blood vessels or other body lumens  
to widen and/or to help keep such lumens open. Typically,  
stents are delivered into the body while in a compressed  
configuration, and are thereafter expanded to a final  
diameter once positioned at a target location within the  
15 lumen. Stents are often used following or substituting for  
balloon angioplasty to repair stenosis and to prevent  
future restenosis and, more generally, may be used in  
repairing any of a number of tubular body conduits such as  
those in the vascular, biliary, genitourinary,  
20 gastrointestinal, respiratory and other systems. Exemplary  
patents in the field of stents formed of wire, for example,

include U.S. Patent Nos. 5,019,090 to Pichuk; 5,161,547 to Tower; 4,950,227 to Savin et al.; 5,314,472 to Fontaine; 4,886,062 and 4,969,458 to Wiktor; and 4,856,516 to Hillstrand; each of which is incorporated herein by reference. Stents formed of cut stock metal, for example, are described in U.S. Patent Nos. 4,733,665 to Palmaz; 4,762,128 to Rosenbluth; 5,102,417 to Palmaz and Schatz; 5,195,984 to Schatz; WO 91 FR013820 to Meadox; and WO 96 03092 to Medinol, each of which is incorporated herein by reference. Bifurcating stents are described in U.S. Patent No. 4,994,071 to MacGregor, and commonly-assigned U.S. Patent Application Serial No. 08/642,297, filed May 3, 1996, each of which is incorporated herein by reference.

For stents to be effective, it is essential that they be accurately positioned at a target location within a desired body lumen. This is especially true where, for example, multiple stenting is required with overlapping stents to cover excessively long regions or bifurcating vessels. In these and other cases, it is often necessary to visually observe the stent both during placement in the body and after expansion of the stent. Various approaches have been attempted to achieve such visualization. For example, stents have been made from radiopaque (i.e., not allowing the passage of x-rays, gamma rays, or other forms of radiant energy) metals, such as tantalum and platinum, to facilitate fluoroscopic techniques. One of the potential problems with such stents, however, is that a useful balance of radiopacity and stent strength is

difficult, if not impossible, to achieve. For example, in  
order to form such a stent of adequate strength, it is  
often necessary to increase stent dimensions such that the  
stent becomes overly radiopaque. Consequently, fluoroscopy  
5 of such a stent after deployment can hide the angiographic  
details of the vessel in which it is implanted, thus making  
it difficult to assess problems such as tissue prolapse and  
hyperplasia.

Another technique that has been used to achieve  
10 the visualization of stents is the joining of radiopaque  
markers to stents at predetermined locations. The joining  
of the stent and marker materials (e.g., stainless steel  
and gold, respectively), however, can create a junction  
potential or turbulence in blood and thus promote  
15 thrombotic events, such as clotting. Consequently, the  
size of the markers is minimized to avoid this problem,  
with the adverse effect of greatly decreasing fluoroscopic  
visibility and rendering such visibility orientation-  
sensitive.

20 Yet another technique that has been used to  
achieve the visualization of stents is to simply increase  
the thickness of such stents to thereby increase  
radiopacity. Overly thick stent struts, however,  
effectively create an obstruction to blood flow. In  
25 addition, design limitations for stents having thick struts  
often result in large gaps between these struts, thus  
decreasing the support of a surrounding lumen.  
Furthermore, overly thick stent struts could adversely

affect st nt flexibility.

There is thus a need f r the increased radiopacity of stents without sacrificing stent mechanical properties or performance. The coating of stents with radiopaque materials is described in U.S. Patent No. 5,607,442 to Fishell et al. According to this patent, the disclosed radiopaque coating is much thicker on longitudinal stent members when compared with radial stent members such that only the longitudinal stent members are visible during fluoroscopy.

#### SUMMARY OF THE INVENTION

The present invention provides stents of optimized radiopacity and mechanical properties.

In one embodiment, the present invention includes a stent comprising a tubular member which comprises struts of a first material, and a first coating on the tubular member. The first coating substantially covers the tubular member and is substantially uniform in thickness. The first coating comprises a second material that is more radiopaque than the first material comprising the struts.

In another embodiment of the present invention, the stent further comprises a second coating disposed between the tubular member and the first coating, wherein the second coating covers only a portion of the tubular member. When the stent is observed with fluoroscopy, the portion where the second coating exists appears darker than where only the first coating exists.

In yet another embodiment of the present invention, the stent is a coated bifurcated stent for positioning in a body lumen that is bifurcated into a trunk lumen and a branch lumen. The stent has trunk and branch legs for positioning in trunk and branch lumens, respectively. In this embodiment, the stent is coated with multiple layers of radiopaque materials such when the stent is observed with fluoroscopy, the branch leg appears darker than the trunk leg.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1A illustrates a coated patterned stent, in accordance with an embodiment of the present invention.

Fig. 1B is a cross-sectional view of a typical strut from the stent of Fig. 1A.

Fig. 2A illustrates a preferred stent configuration in an embodiment of the present invention.

Fig. 2B illustrates a most preferred configuration for a single stent cell, in accordance with an embodiment of the present invention.

Fig. 3A illustrates a patterned stent having multiple coatings thereon, in accordance with an embodiment of the present invention.

Fig. 3B is a cross-sectional view of a typical strut from the stent of Fig. 3A, at a location where two coatings have been applied to the stent.

Fig. 3C is a cross-sectional view of a typical strut from the stent of Fig. 3A, at a location where only

one coating has been applied to the stent.

Fig. 4A illustrates a first coated bifurcated stent, in accordance with an embodiment of the present invention.

5 Figs. 4B-4C illustrate a second coated bifurcated stent, in accordance with an embodiment of the present invention.

#### DETAILED DESCRIPTION

10 The present invention provides optimal radiopacity of stents without sacrificing mechanical properties or performance. A stent according to the present invention is made from a base material having desired mechanical properties (e.g., strength) and coated  
15 with a material to provide optimal radiopacity to the stent. The radiopacity of the stents of the present invention is optimized in the sense that, during fluoroscopic procedures, the stents are entirely visible but are not so radiopaque that angiographic details are masked.  
20 The present invention thus provides for stents that have both the desired mechanical properties of the base material and the desired radiopacity of the coating material. The stents of the present invention have the additional benefit of being manufactured according to  
25 simple and reproducible techniques.

In one embodiment of the present invention, stent 100 is a tubular member 101 comprising struts 110 as shown in Figs. 1A-1B. The term "strut", as used herein, is

intended to mean any structural member of a stent, such as  
any radial, longitudinal, or other members made from wire,  
cut stock, or other materials. Struts 110 comprise a first  
material that is selected for its mechanical properties  
such as, for example, the ability to be delivered into the  
body while in a compressed configuration, the ability to  
expand or be expanded once positioned to a target location,  
the ability to resist recoil, and the ability to hold open  
a body lumen during the stent lifetime. Typical exemplary  
materials for struts 110 include stainless steel and  
nitinol. Stent 100 further comprises a first coating 102  
of a second material that is selected for its radiopacity.  
Coating 102 covers the entire tubular member 101 with the  
result that intersections of the first and second materials  
are not exposed to the exterior of the stent. By not  
exposing intersections of the first and second materials to  
the exterior of the stent, the risks of creating a junction  
potential in the blood and causing the electrolytic  
corrosion of the stent are precluded. Fig. 1B shows a  
cross-sectional view of coating 102 on a typical strut 110  
of stent 100. Although Fig. 1B shows both the strut 110  
and coating 102 to be substantially square in cross-  
sectional shape, the actual cross-sectional shape of either  
or both of these elements is any desired or suitable shape,  
such as circular, oval-shaped, rectangular, or any of a  
number of irregular shapes.

Coating 102 is applied to tubular member 101  
according to any suitable technique such as, for example,

lectroplating, electroless plating, ion beam aided deposition, physical vapor deposition, chemical vapor deposition, electron beam evaporation, hot-dipping or any other suitable sputtering or evaporation process. Coating 5 102 comprises any suitable radiopaque material such as, for example, gold, platinum, silver and tantalum.

The thickness of coating 102 is an important aspect of the present invention. A coating that is too thick will result in a stent that is overly radiopaque, and 10 angiographic details will consequently be masked during subsequent fluoroscopy. In addition, stent rigidity often increases with coating thickness, thus making it difficult to expand the stent for placement in a body lumen if the coating is too thick. On the other hand, a radiopaque 15 coating that is too thin will not be adequately visible during fluoroscopy. Depending on the material and configuration of the tubular member 101, and the material of the coating 102, the thickness of coating 102 is optimized to provide the optimum balance between 20 radiopacity and strength. In general, however, it is preferred that coating 102 be approximately 1-20%, and more preferably approximately 5-15% of the underlying strut thickness. In all embodiments of the present invention, coating 102 is applied to the entire stent such that it is 25 wholly visible during fluoroscopy. Accordingly, any suboptimal expansion at any position along the stent is visible and any deviations from perfect circular expansion can be noticed.

The stents of the present invention are of any suitable configuration, although the patterns and configurations as described in WO 96 03092 and commonly-assigned, allowed U.S. Patent Application Serial No. 08/457,354, filed May 31, 1995 and incorporated herein by reference, are preferred for all embodiments of the present invention. As an example of such a configuration (a close-up of which is shown in Figs. 2A and 2B), stent 100 is a tube having sides that are formed into a plurality of two orthogonal meander patterns intertwined with each other. The term "meander pattern" is used herein to describe a periodic pattern about a center line and "orthogonal meander patterns" are patterns having center lines that are orthogonal to each other.

As shown in Fig. 2A, stent 100 optionally includes two meander patterns 11 and 12. Meander pattern 11 is a vertical sinusoid having a vertical center line 9. Meander pattern 11 has two loops 14 and 16 per period wherein loops 14 open to the right while loops 16 open to the left. Loops 14 and 16 share common members 15 and 17, where member 15 connects from one loop 14 to its following loop 16 and member 17 connects from one loop 16 to its following loop 14. Meander pattern 12 is a horizontal pattern having a horizontal center line 13. Meander pattern 12 also has loops, labeled 18 and 20, which may be oriented in the same or opposite directions. The stent configuration shown in Fig. 2A, with orthogonal meander patterns 11 and 12, provides for a high degree of stent

flexibility to facilitate expansion, yet results in a high degree of rigidity once the stent is expanded. Fig. 2B illustrates a detailed view of a single cell of the most preferred stent configuration of the present invention.

5 In another embodiment of the invention as shown in Figs. 3A - 3C, stent 200 includes a second coating 202 applied between the struts 110 of stent 200 and first coating 102. In distinction to first coating 102, however, second coating 202 covers only a portion or multiple portions of stent 200 so that isolated regions of stent 200 are most visible during fluoroscopy. For example, second coating 202 is applied to one or both of the proximate 111 and distal 112 ends of stent 100, as shown in Fig. 3A. As in the embodiment shown in Figs. 1A-1B, however, first coating 102 covers the entire stent 200 shown in Figs. 3A-3C. Figs. 3B and 3C show cross-sectional views of struts 110 of stent 100 where second coating 202 has and has not been applied, respectively. Such isolated marking is useful for the accurate positioning of the ends of stents, such as, for example, in the case of multiple stenting wherein the overlapping length is important, or, for example, in the case of ostial stenting wherein the position of the stent end relative to the ostium is important.

20 25 Second coating 202 comprises a suitable radiopaque material such as gold, platinum, silver and tantalum, and may be the same or different material as first coating 102. Second coating 202 is applied to stent

200 by any suitable technique, such as those described for  
the application of first coating 102. Second coating 202  
is applied only to a portion or multiple portions of  
tubular member 101, for example, by masking during the  
application of second coating 202 or by isolated etching  
after second coating 202 is applied. It is to be  
appreciated that although coating 202 is herein described  
to be a "second" coating, it is applied to stent 200 before  
the application of first coating 102.

When used, second coating 202 has a thickness  
that will result in increased radiopacity at the portion(s)  
where second coating 202 exists when compared with the  
portion(s) where second coating 202 does not exist.  
Because second coating 202 is applied to only a portion or  
multiple portions of stent 200, it can be thickly applied  
without significantly affecting the resistance of stent 200  
to expand or affecting the visibility of arterial details  
during fluoroscopy. Like first coating 102, the thickness  
of second coating 202 is optimized to provide a desired  
balance between stent radiopacity and other properties. In  
general, however, second coating 202 is typically as thick  
or thicker than first coating 102. When both first and  
second coatings 102, 202 are applied, it is generally  
preferred that the thickness of first and second coatings  
102, 202 are about 1-5% and 5-15% respectively, of the  
underlying stent strut thickness. Furthermore, the  
combined thickness of first and second coatings 102, 202  
typically does not exceed 25% of the underlying stent strut

thickn ss. As an illustrative exempl , second coating 202 is applied to a thickness of about 10 microns onto a stent having 100 micron diam ter struts. First coating 102 is then applied to a thickness of about 1 micron.

5 In another embodiment of the present invention, stent 300 is a bifurcated stent as shown in Fig. 4A. Stent 300 comprises a tubular member 301 that is bifurcated into tubular trunk and branch legs 310, 311 for positioning in trunk and branch lumens of a bifurcated lumen,  
10 respectively. In this embodiment, the entire stent is coated with first coating 102 as described for the embodiments shown in Figs. 1 and 3. Branch leg 311, however, includes second coating 202 disposed between tubular member 301 and first coating 102 such that when  
15 stent 300 is observed with fluoroscopy, branch leg 311 appears darker than the trunk leg 310. The cross-sectional views of the struts of stent 300 thus appear as shown in, Figs. 3B and 3C for branch and trunk legs 311, 310, respectively. Such a configuration is useful for aligning  
20 and inserting branch leg 311 into a branch lumen.

Alternatively, branch leg 311 may be selectively inserted into branch aperture 312 of tubular member 301 so that tubular member 301 and trunk leg 310 are separately delivered into a bifurcated lumen. In this case, tubular member 301 is provided with a branch aperture 312 as shown  
25 in Fig. 4B. When tubular member 301 is delivered to a bifurcated lumen, branch aperture 312 is aligned with the corresponding branch lumen. Tubular member portion 301 of

stent 300 is thereaft r expanded to secure its position in  
the lumen to be treated, and branch leg 311 is delivered  
through branch aperture 312 so that part of branch leg 311  
is positioned into the branch lumen. Branch leg 311 is  
thereafter expanded as shown in Fig. 4C in an amount  
sufficient for its external surface to engage the portion  
of the tubular member 301 defining the branch aperture 312  
and secure the branch leg 311 in the branch lumen and  
tubular member portion 301. In this embodiment of the  
invention, a region 313 surrounding branch aperture 312  
includes both first and second coatings 102, 202 such that  
region 313 is most visible during fluoroscopy. In other  
words, the cross-sectional view of the strut 110 of stent  
300 appear as shown in Fig. 3B for region 313, and as shown  
in Fig. 3C elsewhere. Such a configuration is useful for  
aligning branch aperture 312 with a branch lumen so that  
branch leg 310 is thereafter easily inserted into the  
branch lumen.

The present invention provides stents having  
optimal radiopacity without sacrificing stent properties or  
performance. Those with skill in the art may recognize  
various modifications to the embodiments of the invention  
described and illustrated herein. Such modifications are  
meant to be covered by the spirit and scope of the appended  
claims.

What is claimed is:

1. A stent for deploying within a body lumen, said stent comprising:
  - 2 a tubular member comprising struts which comprise a first material, said tubular member having a proximal end and a distal end and a longitudinal bore therethrough; and
  - 3 a first coating on said tubular member, said first coating substantially covering said tubular member and being substantially uniform in thickness, said first coating comprising a second material;
  - 4 wherein said second material is more radiopaque than said first material.
1. The stent of claim 1, wherein the thickness of said first coating is approximately 1-20 percent of the thickness of an underlying strut.
1. The stent of claim 2, wherein the thickness of the first coating is approximately 5-15 percent of the thickness of an underlying strut.
1. The stent of claim 1, wherein said first coating is approximately 0.5-20 microns in thickness.
1. The stent of claim 1, wherein said first material is

2           selected from the group consisting of stainless steel  
3           and nitinol.

1       6. The stent of claim 1, wherein said second material is  
2           selected from the group consisting of gold, platinum,  
3           silver and tantalum.

1       7. The stent of claim 1, further comprising a second  
2           coating disposed between said tubular member and said  
3           first coating, said second coating covering only a  
4           portion of said tubular member.

1       8. The stent of claim 7, wherein said second coating is  
2           located at said proximal or said distal end of said  
3           tubular member.

1       9. The stent of claim 7, wherein when the stent is  
2           observed with fluoroscopy, said stent appears darker  
3           at the portion where said second coating exists than  
4           where said second coating does not exist.

1       10. The stent of claim 7, wherein the thickness of said  
2           second coating is approximately 1-20 percent of the  
3           thickness of an underlying strut.

1       11. The stent of claim 10, wherein the thickness of the  
2           second coating is approximately 5-15 percent of the  
3           thickness of an underlying strut.

- 1       12. The stent of claim 7, wherein said second coating is
- 2                         approximately 0.5-20 microns in thickness.
- 1       13. The stent of claim 12, wherein said second coating is
- 2                         approximately 5-15 microns in thickness.
- 1       14. The stent of claim 12, wherein said first coating is
- 2                         approximately 1 micron in thickness.
- 1       15. The stent of claim 7, wherein said second coating
- 2                         comprises a material selected from the group
- 3                         consisting of gold, platinum, silver and tantalum.
- 1       16. The stent of claim 1, wherein said tubular member is
- 2                         bifurcated into a trunk leg and a branch leg for
- 3                         positioning in respective trunk and branch lumens of
- 4                         a bifurcated lumen.
- 1       17. The stent of claim 16, further comprising a second
- 2                         coating between said tubular member and said first
- 3                         coating, said second coating covering only said branch
- 4                         leg.
- 1       18. The stent of claim 16, wherein:
- 2                         said tubular member includes a branch
- 3                         aperture;
- 4                         said branch leg may be selectively disposed